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Yeast two-hybrid selection of proteins interacting with human immunodeficiency virus type 1 Vpr identified HHR23A, a
human homologue of the yeast DNA repair protein RAD23, as a specific interactor. A small 57-amino-acid C-terminal portion
of HHR23A was sufficient for Vpr interaction. When introduced into human cells by transfection, full-length HHR23A or its
C-terminal fragments were able to alleviate Vpr-induced cell cycle arrest, suggesting that HHR23A may participate in the
pathway leading to G2 arrest by Vpr. We have also examined the effects of HHR23 on the recently identified transcription
coactivator function of Vpr. The two Vpr functions are independent, since we have identified mutants lacking either the cell
cycle arrest or the coactivator function. Our analysis showed that excess of HHR23A does not affect the coactivator function
of Vpr, while it affects the cell cycle arresting function. Therefore, a simple sequestering model for Vpr in the presence of
excess HHR23A is not supported. We propose that the interaction of HHR23A with Vpr may affect specifically pathways
leading to cell cycle regulation. © 1998 Academic Press
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) encodes
several accessory proteins in addition to the usual com-
plement of retroviral structural proteins (for reviews, see
(Miller and Sarver, 1997; Pavlakis, 1996; Trono, 1995)).
One accessory protein with a role not well understood is
Vpr, a 96-amino-acid protein found both in association
with virions through its interaction with Gag p6 (Lavallee
et al., 1994; Paxton et al., 1993) and in the nucleus of
infected cells (Heinzinger et al., 1994; Wang et al., 1994).
Several functions have been proposed for Vpr, including
nuclear import of the preintegration complex (Heinzinger
et al., 1994), induction of cell growth arrest and differen-
tiation (He et al., 1995; Jowett et al., 1995; Levy et al.,
1993; Re et al., 1995; Rogel et al., 1995), and transactiva-
tion of cellular genes (Cohen et al., 1990). Vpr is clearly
dispensable for viral replication in T cell lines, but growth
of vpr2 molecular clones of HIV-1 in macrophages is
severely delayed (Balliet et al., 1994; Hattori et al., 1990).
Although it is not clear which of the above-mentioned
effects makes Vpr important for virus propagation, some
aspects of HIV-1 pathogenesis may be caused by a
disturbance of cells by Vpr. Expression of Vpr alone was
shown to stop progression of the cell cycle (Jowett et al.,
1995; Re et al., 1995), arresting cells in G2/M phase, and
to cause differentiation of a rhabdomyosarcoma cell line
(Levy et al., 1993). Substantial amounts of Vpr were found
in the medium of infected cultures and in the serum of
infected patients. This extracellular Vpr may exert at least
some of its effects on uninfected cells, which may alter
their ability to be infected and/or may contribute to HIV-1
pathogenesis. Extracellular Vpr was implicated in the
activation of HIV-1 replication in vivo and in the control of
latency (Levy et al., 1994). HIV-2 and simian immunode-
ficiency virus (SIV) express a similar protein, Vpx, in
addition to Vpr (Tristem et al., 1992). Neither protein was
essential for AIDS progression in infected macaques, but
a double mutant lacking both Vpr and Vpx was severely
attenuated (Gibbs et al., 1995). Because Vpr exerts many
of its effects alone rather than in the context of the viral
infection, it acts through certain cellular targets. This
communication describes the identification of one such
target, HHR23A, the human homologue of the yeast re-
pair protein RAD23.
RESULTS AND DISCUSSION
To reveal intracellular interactions responsible for
some of the reported Vpr effects, we used a version of
the yeast two-hybrid system (Finley and Brent, 1995) with
LexA-Vpr fusion as a bait. Numerous clones able to
activate both reporter genes in the galactose-dependent
manner (see Materials and Methods) were picked up in
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a primary screen. To find candidate proteins interacting
with Vpr, but not with other LexA fusions, we used the
interaction mating test (Finley and Brent, 1994), in which
yeast strains containing different library plasmids were
mated with strains of the opposite mating type contain-
ing either Vpr or other HIV-1 protein fusion baits (Fig. 1).
We were interested in proteins interacting specifically
with Vpr. Only about 10% of the clones that were picked
up in the primary screen passed this last test. Sequenc-
ing followed by the BLAST search of the available se-
quence databases showed that all the inserts coding for
proteins demonstrating specific interaction with Vpr
came from only two genes. Here we present our analysis
of the interaction with the product of the one gene,
HHR23A. The significance (if any) of Vpr’s interaction
with the second gene product is under investigation and
will be described elsewhere. HHR23A (Masutani et al.,
1994; van der Spek et al., 1996a) is the human homo-
logue of the yeast excision-repair gene RAD23 (Mueller
and Smerdon, 1996; Watkins et al., 1993). We identified
four independent Vpr-interacting fusions of various sizes
containing the C-terminus of the protein (Fig. 2). The
shortest fusion shows that the Vpr-interacting part of the
protein is carried within 57 C-terminal amino acids,
roughly corresponding to the conserved internal repeat
of RAD23 (van der Spek et al., 1996b). Both Vpr and
HHR23A are localized to the cell nucleus (van der Spek
et al., 1996a), making their interaction potentially rele-
vant.
To verify that the identified interaction takes place in
mammalian cells and has biological significance, we
expressed HHR23A or its 57-amino-acid C terminal frag-
ment in human cells together with Vpr (Fig. 3). Vpr ex-
pression under the control of CMV promoter, or in the
context of the NL4-3 HIV-1 molecular clone, efficiently
increased the fraction of cells in the G2/M phase of the
cell cycle. Cotransfection of plasmids coding for either
full-length HHR23A or a 57-amino-acid C-terminal frag-
ment of the protein significantly reduced this Vpr effect.
In addition, the 168-amino-acid fragment of HHR23A (cor-
responding to clone HP15) was tested with similar re-
sults (data not shown). Expression of GFP in the Vpr-
FIG. 1. Mating test for the Vpr-interaction specificity. Haploid bait strains are derivatives of RFY206 (Mata his3 leu2 lys2 ura3 trp1) transformed with
the lacZ reporter plasmid pSH18-34 (URA31) and the indicated bait-expressing plasmids (HIS31, based on vector pEG202), and are streaked in
horizontal lines. ‘‘Control’’ represents a preexamined LexA fusion which activates transcription. Haploid prey strains derived from EGY48 (Mata his3
leu2<3Lexop-LEU2 ura3- trp1 LYS2) contain individual plasmids from the cDNA acid-fusion library in vector pJG4-5 and are streaked in vertical lines.
Diploids forming in the intersections were tested for lacZ activity (top panel) and ability to grow without leucine (bottom panel). Arrows indicate clones
that we considered specific for the interaction with Vpr.
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expressing cells did not result in changes in the cell
cycle profile, indicating that the effects of HHR23A on
alleviation of the G2 cell cycle arrest caused by Vpr were
specific. We can draw the following conclusions from
these experiments. First, the interaction between Vpr and
HHR23A detected in the yeast two-hybrid screen also
takes place in human cells and is independent of LexA
and acidic activator parts of the yeast constructs. Sec-
ond, the interaction of the overproduced HHR23A with
Vpr prevents the latter from blocking the cell cycle. Third,
overproduction of HHR23A (or its fragments) by itself
does not affect the cell cycle.
There are two possible explanations for the observed
reduction of the Vpr-induced cell cycle effect by HHR23A.
The simplest explanation is that the interaction of Vpr
with endogenous HHR23A mediates cell cycle arrest and
that HHR23A overproduction in excess of Vpr overcomes
this effect. The other possibility is that HHR23A-Vrp bind-
ing prevents Vpr from interacting with another cellular
target responsible for the cell cycle block. We favor the
first explanation, however, because the 57-amino-acid
C-terminal fragment of HHR23A, being considerably less
bulky, is still effective in reversing Vpr-induced cell cycle
arrest. Assuming that this fragment occupies the site that
Vpr uses for binding to its cellular target responsible for
cell cycle arrest, the simplest explanation is that this
target is HHR23A itself. We hope to distinguish between
these two possibilities by analyzing the cell cycle effect
of Vpr mutants unable to bind HHR23A. We are currently
selecting such mutants.
The possibility that HHR23A prevents Vpr action by
titrating it out, or sequestering it somewhere in the cell,
or causing Vpr degradation could be addressed by fol-
lowing HHR23A action on any effect of Vpr distinct from
the cell cycle arrest. Recently Vpr has been proposed to
act as a coactivator of the glucocorticoid receptor (Kino
et al., 1998). Vpr interacts directly with the glucocorticoid
receptor in vitro and is coprecipitated by anti-glucocorti-
coid receptor antibodies in extracts of glucocorticoid-
treated cells, suggesting that it exerts its effects within
the glucocorticoid-induced transcription initiation com-
plex. Vpr contains the signature motif LXXLL that is also
present in nuclear receptor coregulators, such as SRC-1
and CBP/p300, and is responsible for their interaction
with the glucocorticoid and other nuclear receptors
(Heery et al., 1997; Torchia et al., 1997). We used Vpr
mutants to show that glucocorticoid receptor coactiva-
tion and cell cycle arrest are, indeed, two separate func-
tions. Mutation L64A in the coactivator signature motif
disrupts the ability of Vpr to influence transcription of
glucocorticoid-responsive genes and makes this mutant
a dominant negative inhibitor of the native protein (Kino
et al., 1998). The same mutation does not influence the
ability of Vpr to block the cell cycle (Fig. 4). Mutation
R80A has a reciprocal effect: it prevents the cell cycle
block (as also shown previously by others (Di Marzio et
FIG. 2. Independent clones containing fragments of HHR23A isolated by their ability to interact with Vpr. Numbers correspond to the full-length
HHR23A mRNA (marked HHR23A). Boxes correspond to open reading frames. Gray boxes at the N-termini of clones isolated from the cDNA library
represent the vector part of a protein fusion, including the nuclear localization signal, the B42 activation region, and the influenza hemagglutinin
epitope tag. The upper lane represents (approximately in scale) the domain organization of the protein, showing the positions of the ubiquitin-like
N-terminal part, internally repeated sequences, and proline-, alanine-, serine-, and threonine-rich (PAST) regions (van der Spek et al., 1996b).
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al., 1995)) but does not affect GR coactivator activity (Fig.
4). Remarkably, HHR23A weakly increased the ability of
Vpr to stimulate glucocorticoid receptor (Fig. 5), while it
dramatically suppressed the Vpr-induced cell cycle ar-
rest. Therefore, HHR23A does not block Vpr activity in
general, but specifically interferes with its cell cycle
action (compare Figs. 3 and 5). Western blot analysis
also showed that HHR23A does not cause Vpr degrada-
tion (Fig. 3, insert).
The role of cell cycle arrest in HIV-1 expression is not
clear. The following facts, however, argue in favor of
some important function for the arrest. Vpr is conserved
among all primate lentiviruses, and its ability to cause
cell cycle arrest is also conserved. This property, how-
ever, is species specific, with Vpr of a particular virus
being more effective in blocking cells of its natural host
(Stivahtis et al., 1997). HIV or SIV isolated from chroni-
cally infected cell lines is vpr2; otherwise, infected cells
would be unable to divide (Rogel et al., 1995). Introduc-
tion of such a virus in animals results in selection of vpr1
virus (Lang et al., 1993), indicating that the Vpr function is
of clear advantage in vivo.
Several approaches have been used to identify the
cellular targets of Vpr. Protein bands were identified by
coimmunoprecipitation with Vpr or by binding to immo-
bilized Vpr (Rafaeli et al., 1995; Zhao et al., 1994). Neither
of these putative targets was functionally characterized,
but one of them was coimmunoprecipitated with Vpr and
the activated glucocorticoid receptor complex (Rafaeli et
al., 1995). As mentioned above, glucocorticoid receptor
itself is a Vpr-interacting protein (Kino et al., 1998). Use of
the yeast two-hybrid system by others led to the identi-
fication of a repair enzyme uracil–DNA–glycosylase
(UNG), as a Vpr-interacting protein (Bouhamdan et al.,
1996). Although this binding was confirmed in vitro, it did
not inhibit UNG activity and its functional importance for
Vpr action was not demonstrated. Vpr-induced cell cycle
arrest is independent of this interaction (Selig et al.,
1997).
The data reported in this paper implicate HHR23A as
FIG. 3. Effect of HHR23A on Vpr-induced cell cycle arrest. 293T cells were cotransfected with 0.5 mg of GFP expression plasmid, 0.5 mg of pNL4-3
(top panel) or pVpr (bottom panel) and, where indicated, 2 mg of the expression plasmid encoding either full-length HHR23A or its 57-amino-acid
fragment corresponding to the yeast clone HP50 (see Fig. 2). Two days after transfection, the cells were stained with Hoechst dye and analyzed by
flow cytometry. The diagrams show the number of cells (vertical axis) versus fluorescence intensity indicating the DNA content (horizontal axis). The
insert shows Western blot detection of Vpr in the trasfected cells (from a separate experiment) in the absence or the presence of cotransfected
full-length HHR23A. Proteins transferred to Immobilon P (Millipore) membrane were stained with anti-Vpr rabbit serum followed by goat anti-rabbit
alkaline phosphatase conjugate.
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a potential mediator of Vpr-induced cell cycle arrest. The
yeast homologue of HHR23A, Rad23, is a UV-inducible
protein (Madura and Prakash, 1990) required for efficient
nucleotide-excision repair, both general and transcription-
coupled (Guzder et al., 1995; Mueller and Smerdon, 1996;
Wang et al., 1997). It has been shown to promote complex
formation between transcription factor TFIIH and the DNA
damage recognition protein Rad14 (Guzder et al., 1995).
Both human and mouse homologues have been cloned,
and each species has two homologous genes, named
HHR23A and HHR23B. It is not clear whether they have
distinct cellular functions (Masutani et al., 1994; van der
Spek et al., 1996b). Part of the mammalian Rad23B is found
in a complex with xeroderma pigmentosum group C protein
(XP-C) (van der Spek et al., 1996a) and is stimulatory for the
nucleotide excision repair activity of XP-C in vitro (Suga-
sawa et al., 1996). Yeast, mouse, and human Rad23 proteins
share the following features (see Fig. 2): An 80-amino-acid
ubiquitin-like domain present at the N-terminus, which is
essential for biological function of yeast Rad23 (Watkins et
al., 1993). It is followed by a nonconserved region com-
posed mainly (86%) by proline, alanine, serine, and threo-
nine (PAST domain). The rest of the protein contains two
copies (one at the C-terminus) of an internally repeated
50-amino-acid element. This internally repeated sequence
is fully conserved between human and mouse and is sim-
ilar to a C-terminal extension of the bovine ubiquitin-conju-
gating enzyme E2(25K) (van der Spek et al., 1996b). It is the
C-terminal copy of this repeated sequence that overlaps
with the Vpr-interacting region of the protein. Provided there
is a high similarity of the C-terminal copy of the internal
repeat between HHR23A and B, it is not surprising that Vpr
also interacts with HHR23B (Withers-Ward et al., 1997),
although only HHR23A clones were picked up by the two
hybrid screen.
If HHR23A is indeed the mediator of Vpr-induced cell
cycle arrest, what may be the possible mechanism? One
option is that by binding the repair protein, Vpr mimics
DNA damage and triggers a checkpoint mechanism (for
a review, see Elledge, 1996) blocking cells in G2. There
is circumstantial evidence supporting such a view (Poon
et al., 1997). Other workers argue, however, that the
mechanism of Vpr-induced arrest is different from the
DNA damage checkpoint (Bartz et al., 1996) with some
cells accumulating DNA to polyploid levels, although the
data are also indirect. Another possibility is indicated by
studies of yeast RAD23. Inactivation of this protein to-
gether with DSK2, another protein that also has an ubiq-
uitin-like N-terminus, prevents proper duplication of spin-
dle pole bodies (Biggins et al., 1996). If this function is
conserved in mammalian cells, the RAD23 homologue
may have a direct role in cell cycle progression.
FIG. 4. Cell cycle arrest and glucocorticoid receptor coactivation are two independent effects of Vpr. The top panel shows the effect of Vpr mutants
altered in positions 64 or 80 on the DNA content of the transfected 293 cells. The experiment was done as described in the legend to Fig. 3. The
bottom panel shows the ability of the same Vpr mutants to stimulate dexamethasone (Dex) response of the MMTV promoter. Human rhabdomyo-
sarcoma A204 cells were transfected with the reporter construct containing the luciferase gene under the control of the MMTV promoter together with
the indicated Vpr construct. The diagram shows the ratio of the promoter activity (as measured by luciferase assay) in the transfected cells in the
presence of Dex to the activity in its absence.
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After the completion of this work, a study by Chen and
co-workers was published (Withers-Ward et al., 1997)
describing very similar findings. Our demonstration that
HHR23A inhibits the cell cycle effect, but not the tran-
scriptional coactivator effect, of Vpr is strong new evi-
dence (though not a proof) in favor of human Rad23
homologue HHR23A being a component of a cell cycle
regulatory pathway with which Vpr interferes.
MATERIALS AND METHODS
Plasmids
Vpr bait plasmid for the yeast two-hybrid screening
was prepared by cloning of a PCR-amplified Vpr frag-
ment from the NL4-3 molecular clone of HIV-1 into the
pEG202 LexA fusion vector (Finley and Brent, 1995). Vpr
plasmids for expression in human cells were con-
structed by cloning of PCR fragments produced from
pNL4-3 or pNLA1 into pcDNA3 (Invitrogen, Carlsbad,
CA). The L23A, L26A, L64A, and R80A mutants of Vpr
were prepared by PCR-assisted in vitro mutagenesis of
the pcDNA3-Vpr expression plasmid. HHR23A expres-
sion plasmids were prepared by insertion of the full-
length HHR23A coding region (or its fragments corre-
sponding to the yeast prey plasmids) obtained by RT–
PCR from total cellular RNA in pcDNA3.
Yeast two-hybrid system
We used a version of the yeast two-hybrid system (Fields
and Song, 1989; Gyuris et al., 1993) developed in R. Brent’s
laboratory (Finley and Brent, 1995; Gyuris et al., 1993). LexA
fusion vector pEG202 was used to prepare bait plasmids.
The HeLa cell acid-fusion library used was constructed by
J. Gyuris. The interaction between the DNA-binding LexA-
Vpr fusion protein and target proteins was detected by
transcriptional activation of two reporter genes: lacZ and
LEU2. Only clones with both reporter genes activated were
analyzed further. The primary selection was for cells able to
form colonies in 3 to 5 days on plates without leucine.
Because the prey library fusions were under the control of
the GAL1 promoter and therefore were synthesized in the
presence of galactose but not glucose, all putative positive
clones were additionally screened for activation of b-galac-
tosidase and for the dependence of both the ability to grow
without leucine and b-galactosidase activity on the pres-
ence of galactose. Gal-dependent LEU1, b-gal1 colonies
were used to rescue library plasmids. To study the speci-
ficity of the interaction, we used the interaction-mating test
(Gyuris et al., 1993).
Cell transfections
Human embryonic kidney 293T cells were transfected
by the calcium phosphate precipitation method as de-
scribed (Felber et al., 1989). The total amount of DNA in
the transfection mixtures was adjusted with Bluescript
plasmid DNA to 5 mg per 60-mm plate. Human rhabdo-
myosarcoma A204 cells were transfected using lipofec-
tin (Life Technologies, Gaithersburg, MD). The cells were
treated with 1027 M dexamethasone 24 h after transfec-
tion and the cell lysates were prepared after another 24 h
of incubation. Luciferase activity and protein concentra-
tion were measured as described (Karl et al., 1996; Smith
et al., 1996).
Flow cytometry
Two days after transfection, the cells were stained
with 10 mg/ml of Hoechst 33342 (Molecular Probes, Eu-
gene, Oregon) for 1 h at 37°C, collected, washed once
with PBS, and analyzed by flow cytometry for DNA con-
tent, indicative of the phase of the cell cycle. When HIV-1
molecular clone was used for transfection, the cells were
fixed with 2% paraformaldehyde prior to flow cytometry to
inactivate the virus. To distinguish transfected versus
untransfected cells, we included a GFP-encoding plas-
mid in all the transfections, allowing us to examine the
DNA content per cell in green fluorescent (transfected)
cells only. Use of the Hoechst 33342 dye does not re-
quire cell fixation and permeabilization interfering with
GFP fluorescence.
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FIG. 5. HHR23A stimulates rather than inhibits the ability of Vpr to
activate glucocorticoid response. MMTV promoter-driven luciferase
expression was used to measure glucocorticoid response. A204
cells were transfected with the reporter construct together with 0.6
mg of Vpr construct or Vpr and HHR23A (2 mg) constructs. Luciferase
activity was measured in the absence and in the presence of
dexamethasone (1027 M).
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